Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Biden sets out plan to share 25 mln COVID-19 vaccine doses with the world

Thu, 03rd Jun 2021 16:56

(Adds reaction, background)

By Jeff Mason and Carl O'Donnell

WASHINGTON, June 3 (Reuters) - The White House laid out a
plan on Thursday for the United States to share 25 million
surplus COVID-19 vaccine doses with the world and said it would
lift some restrictions to allow other countries to more easily
buy U.S.-made supplies for vaccine production.

President Joe Biden said the United States would share the
vaccines without expectation of political favors in return. He
has pledged to share some 80 million COVID-19 vaccines
internationally this month.

The United States will donate nearly 19 million doses
through the COVAX international vaccine-sharing program, Biden
said in a statement. Through COVAX, some 6 million doses would
go to Latin America and the Caribbean, about 7 million doses to
South and Southeast Asia and roughly 5 million to Africa.

The remaining doses, amounting to just over 6 million, would
go directly from the United States to countries including
Canada, Mexico, India and South Korea, he said.

"We are sharing these doses not to secure favors or extract
concessions," Biden said. "We are sharing these vaccines to save
lives and to lead the world in bringing an end to the pandemic,
with the power of our example and with our values."

Although the United States is working through the COVAX
facility co-run by the World Health Organization, the White
House retains final say in which countries receive U.S. doses
and how many, said national security adviser Jake Sullivan.

The White House will base donation decisions on "factors
included achieving global coverage, responding to crises ... and
helping as many countries as possible," Sullivan said, adding
the United States intends to prioritize its neighbors, including
Canada, Mexico and countries in Central and South America.

Reuters reported last month that the United States was
considering prioritizing its own hemisphere, with Latin America
a beneficiary.

The 25 million doses would be delivered quickly, with some
going out as soon as Thursday, the White House said.

Biden has come under pressure from the world community to
share the U.S. surplus of COVID-19 vaccines.

For months, the White House remained focused on getting
Americans vaccinated as the coronavirus killed more than half a
million people in the United States.

But the president has promised the United States would
become a supplier to other countries and pledged to send abroad
at least 20 million doses of the Pfizer Inc/BioNTech SE
, Moderna Inc and Johnson & Johnson
vaccines, on top of some 60 million AstraZeneca Plc
doses he had already planned to give to other countries.

The 25 million doses Biden announced on Thursday will not
include supply from AstraZeneca, the White House said.

International organizations including the United Nations and
the World Bank welcomed the announcement. "It’s a good start,
and I am hoping that more doses will be made available," World
Bank President David Malpass told Reuters.

LIFTING SOME RESTRICTIONS

The White House is also removing special powers it granted
through the Defense Production Act (DPA) to certain vaccine
makers that received U.S. funding but do not yet have U.S.
approvals, including AstraZeneca, Sanofi SA/GlaxoSmithKline Plc
, and Novavax Inc.

The DPA ratings give U.S. producers priority access to
supplies and equipment needed to manufacture the vaccines that
are in short supply around the world. Lifting them could free up
raw materials for major vaccine makers elsewhere, especially the
Serum Institute of India (SII).

Invoking the DPA helped build a huge local vaccine
production system, while some companies overseas have struggled
to get needed supplies to ramp up vaccine production.

SII, the world's largest vaccine maker and a top supplier of
COVID-19 shots to low- and middle-income countries, had
criticized the use of the DPA, and Reuters reported in May that
a shortage of U.S.-made raw materials would hit production of
Novavax's vaccine.

"That is a start, at least – the Biden administration acting
to stop harming the global response. Now, we need a DPA for the
world," said Peter Maybarduk, access to medicines director at
consumer watchdog Public Citizen, which has argued the United
States should use the DPA to scale up global vaccine production.

White House COVID-19 adviser Jeff Zients said the United
States would continue to donate additional doses throughout the
summer as more supply becomes available.

Concern has been growing about the huge disparity in
vaccination rates in developing countries versus advanced
economies.

The International Monetary Fund and World Bank on Thursday
urged the Group of Seven advanced economies to release any
excess COVID-19 vaccines to developing countries as soon as
possible, and called on manufacturers to ramp up production to
benefit poor countries.

Pfizer has begun independently exporting millions of its
U.S.-made shots largely to countries in Central and South
America, Reuters reported last month.

Many Latin American countries have a dire need for COVID-19
vaccines as they combat outbreaks. Brazil has been one of the
world’s hardest-hit countries by the pandemic, reporting more
than 15 million cases and 400,000 deaths.

Peru this week revised its COVID-19 death toll, making it
the country with the worst per-capita fatality rate.
(Reporting by Jeff Mason and Carl O'Donnell; additional
reporting by Allison Martell and Andrea Shalal; Editing by Bill
Berkrot and Peter Cooney)

More News
12 Feb 2024 17:11

London close: Stocks finish higher after very quiet Monday

(Sharecast News) - London markets managed modest gains by the close of a subdued trading session on Monday, with no significant corporate or economic catalysts driving movements.

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.